Urinary Tract Infection (UTI) Clinical Trials

Urinary Tract Infection (UTI) Vaccine Clinical Trials

Urinary tract infections (UTIs) vaccine and treatment clinical trials are being conducted in 2024. To register for a clinical trial, please visit this PVax Clinical Trials Link.

Recurrent UTI Vaccine Information

Uromune™ (MV140) is a self-administered oral spray vaccine for recurrent urinary tract infections approved for adults in certain countries. 

Urinary Tract Infection Treatments

RECCE® 327 is an intravenous and topical therapy developed to treat serious UTI/Urosepsis infections caused by Gram-positive and Gram-negative bacteria, including their superbug forms.

UTILITY therapeutics Ltd. pivmecillinam (Pivya™, Selexid, Melysin, Coactab) tablets are approved for the treatment of female adults with uncomplicated urinary tract infections (UTIs). Pivmecillinam is expected to be available in the USA in 2025.

UTI Vaccine Appointment Requests

UTI vaccination requests can be submitted using this PVax Appointment link.